| Sep 9 |
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
|
| Sep 4 |
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 27 |
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
|
| Aug 26 |
RVPH: August OLE Update
|
| Aug 21 |
Reviva Pharmaceuticals stock falls after it prices $5M offering
|
| Aug 21 |
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
|
| Aug 15 |
Reviva Pharmaceuticals GAAP EPS of -$0.26
|
| Aug 14 |
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 6 |
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis
|
| Jul 9 |
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
|
